Novo Nordisk’s new top executive will need to help the company close the gap with Eli Lilly, fend off emerging rivals and ...

Over the past six months, Eli Lilly has earned significant wins over its Denmark-based rival and is still at it. Recent clinical trial results Eli Lilly released suggest that it is building a lead in ...

Drug manufacturers to focus on China and Japan, where penetration is low and innovation continues to emerge, Morgan Stanley ...

(MENAFN- GlobeNewsWire - Nasdaq) Explore the GLP-1R agonists market, uncovering new opportunities for repurposing beyond type 2 diabetes and obesity ... Novo Nordisk and Eli Lilly and potential ...

In December of last year, Eli Lilly directly compared the weight ... and that Zeb Bound is expected to soon seize the lead in the obesity market. There are analyses suggesting that Zeb Bound's ...

I believe orforglipron’s approval should finally lead to widespread and global availability of obesity medicines ... improve Eli Lilly’s leadership position in this market and these results ...

While Eli Lilly entered the market later, it is emerging as the ... "While Novo [Nordisk] took a commanding early lead in the obesity duopoly, they have ceded ground at a critical moment when ...

Despite beating on its earnings Thursday, pharma giant Eli Lilly (LLY) suffered a nearly 12% loss in its stock, losing more than $90 billion in market cap ... on new branded obesity scripts ...